QURE News

Pomerantz LLP Updates Investors on Legal Action Brought Against uniQure N.V. – QURE

Pomerantz LLP Reminds Shareholders with Losses on their Investment in uniQure N.V. of Class Action Lawsuit – QURE

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Pomerantz LLP Shares Class Action Details With Shareholders in uniQure N.V. – QURE

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm

QURE INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 Ready to Announce with Confidence?

QURE Stockholders Have Opportunity to Lead uniQure N.V. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

Pomerantz LLP Reminds Shareholders with Losses on their Investment in uniQure N.V. – QURE